ADMA Biologics Inc (ADMA)

Nasdaq: ADMA · Biological Products, (No Diagnostic Substances) · Ramsey, NJ · filing with the SEC since 2006

Full chart Alerts Compare

Grade6.5

◀ Past 6.8● Present 7.8▶ Future 4.7

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$510M+19.6%

Net income$147M-25.7%

Earnings per share$0.60-25.9%

Operating cash flow$50.4M-57.5%

Cash$87.6M-15.0%

Debt$72.1M-0.3%

Shareholders’ equity$477M+36.8%

Shares, diluted244.9M+0.6%

Return on equity30.8%

The recordfrom its filings

Filings in 202651

Newest filingNov 10 · SCHEDULE 13G

Annual reportFeb 25, 2026

Quarterly reportNov 4, 2026

Next report due10-K by Mar 1

Insider sales, 12 months$3.3M

Insider buys, 12 months$500,000

Patents granted11

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Revenue $519MNet income $182MCash from operations $141Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 144

Notice of intended sale

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Aug 7, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Jul 28, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Jul 17, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

ADMA Biologics Inc is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Ramsey, NJ. ADMA Bio Manufacturing was 97% of fiscal 2025 revenue.

Newest on the record

Large holder notice on Nov 10. Before it, insider trade report on Nov 5.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 1, 2027.

About ADMA

ADMA Biologics Inc is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Ramsey, NJ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $510 million and a profit of $147 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersRamsey, NJ

Business modelProduct business

ExchangeNasdaq

Filing since2006

Fiscal year endsDec 31

SEC number (CIK)1368514

Peers on fileAUTL, FDMT, TARS, ADPT

Who runs it

Financial performance

In fiscal 2025 ADMA Biologics’s revenue was $510.2 million, up 19.6% from $426.5 million the year before. Net income was $146.9 million, down 25.7%.

Annual report, filed Feb 25, 2026.

Financial statements

The grade

ADMA Biologics grades 6.5 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). All nine metrics are read as filed.

◀ Past6.8

● Present7.8

▶ Future4.7

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton ADMA · research, not advice